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Abstract
The products of arachidonic acid (AA) metabolism in platelets play an important role in platelet shape
change, adhesion and aggregation which may participate in the pathogenesis of ischemic heart disease
and thrombosis. Since lipoproteins are also involved in the pathogenesis of thrombo-embolic disordets,
the effects of human lipoproteins (HDL, LDL, VLDL) on AA metabolism in human platelets was
investigated. Lipoproteins were separated by density gradient zonal ultracentrifugation. The effects of
lipoproteins on production of AA metabolites in human platelets i.e., thromboxane A2 (TXA2) and
hydroxy-eicosatetraenoic acids (HETEs) were examined using radiometric thin layer chromatography
coupled with automated data integrator system. In human platelets, HDL inhibited 12-HETE and TXA
2 fonnation in a concentration-dependent manner. LDL had a strong inhibitory effect on TXA 2
production and a weak inhibitory effect on 12-HETE production. VLDL had no effect on platelet AA
metabolism. These findings point to a new facet of lipoproteins action and suggest.that lipoproteins
may have a physiological role in the regulation of AA metabolism in platelets (JPMA 47:84,1997).
Introduction
The pmducts of arachidonic acid (AA) metabolism in platelets include thromboxane A2 (TXA2) and
hydroxy-eicosatetraenoic acids (HETEs). These metabolites are well characterized mediators of
inflammatory and immunological reactions in the pathophysiology of several disorders, where they
may act in an autocrine or paracrine fashion1,2. TXA2 is a vasoconstrictor and exerts a strong proagglegatory effect on platelet agpegation whereas 12-HETE is a potent chemotactic factor1,2. TXA 2
receptors on platelets are coupled with guanme nucleotidebindingproteins (G-proteins) of the class Gq
family3. Activation of Gq proteins generates second messengers, inositol triphosphate (IP 3) and
diacyiglycerol (DAG) which in turn causes release of intracellular calcium and activation of protein
kinase C, respectively4.
Lipoproteins are macromolecular complexes canying various lipids and proteins in the plasma. The
principal biologic function of the lipoproteins is the transport of water-insoluble lipids within the
bloodstreamfrom the sites of absorption or synthesis to the sites of storage or metabolic utilization5.
The lipoproteins are subdivided into chylomicrons, very low density lipoproteins (VLDL), low density
lipoproteins (LDL) and high density lipoproteins (HDL). These lipoprotein classes vary in their density,
size, source ofongin, lipid and protein compositionand functions6. The major function of chylomicrons
is transport of dietary triglycerides whereas VLDL is primarily involved intransport of endogenously
synthesized triglycerides and some cholesterol. LDL is mainly responsible for the transport of
cholesterol esters of hepatic and intravascular origin to peripheral cells and is a major risk factor for
coronary heart disease7. On the other hand, HDL is involved in ‘reverse cholesterol transport’ whereby
excess cholesterol from peripheral cells is returned to liverforcatabolism andby virtue of this effect
HDL is considered a protective factor against coronary heart disease7. Recent studies have
demonstrated that lipoprotems may also have other functions. Beitz and Forster have shown that HDL

stimulates, whereas LDL inhibits the prostacyclin synthetase activity of pig aortic microsomes8. On the
other hand, Shakhov et at9 have recently demonstrated that both LDL and HDL stimulate the formation
of 6-keto-PGF la (a stable degradation product of prostacyclin) in cultured human and rabbit aortic
smooth muscle cells. We have also shown that LDL. HDL and VLDL inhibited the biosynthesis of PGE
2 and 6-keto-PGFla in bovine seminal vesicle microsomes10.
While all of these studies have focused on the effects of lipoproteins on cyclooxygenase pathway of AA
metabolism, very little is known about the effects of lipoproteins on the lipoxygenase pathway.
Platelets are a unique model for studying A.A metabolism as both cyclo-oxvgenase and lipoxygenase
pathways can be simultaneously studied. In human platelets, AA is primarily metabolized by cyclooxygenase and lipoxygenase pathways into TXA2 and 12-HETE respectively TXA 2 is very unstable
and is rapidly hydrolyzed to a stable metabolite TXB 2 which can be measured and reflects the rate of
TXA2 formation. In order to further define the effects of human lipoproteins on AA metabolism, in this
study we have examined the effects of HDL, LDL and VLDL on metabolic disposition of radio-labelled
AA in human platelets.
Material and Methods
Materials
Arachidonic acid (grade 1: 99% pure) and reduced glutathione were purchased from Sigm Chemical
Company (St. Louis, MO, USA). C] AA (sp. act. 58 mci/mmol), [S3H] thromboxane B2 (sp. act. SA
120 Ci/mmol) and 12-hydroxy-~3 H]-eicosatetmenoic acid .(12-HETE) (sp. act.
100 Ci/mmol) were obtained from Amersham International plc, U.K. All other chemicals used were of
analytical grade.
Preparation of Lipoproteins
Blood obtained from 12 hours fasted healthy volunteers (age range 20-30 years) was collected in EDTA
(1 mg/ml) containing tubes. The plasma lipoproteins were separated by sequeritial density gradient
ultracentrifuption using the method of Havel et al11 as described earlier 2 After isolation, each
lipoprotein fraction was sterilized by filtration through a Millipore (0.45 um) filter (Millipore Corp,
Bedford, MA) and stored at 4°C. The protein content of each lipoprotein fraction was determined by
the method of Lowry et al13 3using human serum albumin as standard and adjusted to initial protein
concentration for each batch. The homogeneity of each lipoprotein fraction was confirmed by agarose
gel. electrophoresis and the purified lipoproteins were used within one month of preparation.
Arachidonic acid metabolism by human platelets
Human blood platelets from donors were obtained in plastic bags containing 30-40 ml of concentrated
platelet-rich plasma (PRP) from The Aga Khan University Hospital
Laboratory. The PRP was centrifuged at 100 g for 5 min and the supernatant was discarded. The
remaining PRP was then centrifuged at 1200 g for 20 min and the sedimented platelets were washed
twice with ice-cold 50 mM. phosphate buffer (pH 7.4) containing 0.15 M sodium chloride and 0.2 mM
EDTA.
After centrifugation platelets were resuspended in the same. buffer without EDTA at the initial PRP cell
concentration. The PRP suspension was homogenized at 4°C using a polytron homogenizer for 15
seconds and the homogenate was centrifuged at 1,200 g for 20 min. AA metabolism in human platelets
was studied as described in our earlier publications14,15. Briefly, 300 uL of the supematant (containing
0.4 mg of protein) was incubated with 10 ug unlabelled AA and 0.1 uCi [1-14C] AA in the absence and
presence of different concentrations of HDL, LDL and VLDL. After 15 min with gentle shaking at 37c
the reaction was stopped by addition of citric acid and ethyl acetate. The reaction mixture was vortexed
and centrifuged at 600 g for 5 min at 4C, the organic layer was separated and evaporated to dryness

under nitrogen,
The residues were dissolved in 50 ul of et hanol and 20 ul were applied to silica gel G thin layer
chromatography (TLC) plates (Analtech, Delaware, USA). The AA, TXB2 (a stable degradation
product of TXA2) and 12-HETE standards were spotted separately. The plates were developed in
ether/petroleum ether/acetic acid (50:50:1 by volume) to a distance of 17 cm. By use of this solvent
system the various lipoxy genase products (HETEs) were separated with TXB2 and PGs remaining at
the origin16. The solvent system used for the separation of various PGs and TXB2 in dried organic
extracts of platelets was ethyl acetate: isoctane: water: acetic acid (11:5:10:2, v/v,upper phase).
Radioactive zones were located and quantified by the use of a Berthold TLC linear analyzer and
chromatography data system (Model LB 511, Berthold, Germany).
Statistics
The data are presented as means+s.e.m. The control values were compared with those obtained in the
presence of various lipoproteins between two groups was calculated by using students unpaired t-test.
Comparisons among more than two groups were performed by one-way analysis of variance (ANOVA)
using Crunch statistical software (Oakland, CA) as described earlier17.
Results
The effect of different concentration of HDL on [1-14C] AA metabolism in human platelets is
presented in Figure 1.

HDL decreased TXA2 formation by 23+3 % (p<0.05), 37+6 % (<0.01) and 72+3 % (p<0.001) at the

protein concentrations of 0.07, 0.7 and 2.1(mg protein/ml assay volume) respectively (Figure 1A).
HDL also had a concentration dependent inhibitory effect on 12- HETE formation in platelets. A
decrease of 12+1 % (P<0.05), 58+4 % (P<0.01) and 81±3 % (P<0.001) in 12-HETE formation at
similar protein concentrations was observed with HDL (Figure 1B).

The effect of different concentration of LDL on -14C] AA metabolism in human platelets is presented
in Figure 2.

LDL had a concentration-dependent inhibitory effect on TXA2 formation (Figure 2A) which was
decreased by 15±2 %(p

The effect of . different concentration of VLDL on AA metabolism in humanpiatelets is shown in
Figure 3.

There was no significant inhibitory or stimulatoty effect of VLDL at similar protein concentrations of
0.07, 0.7 and 2.1 (mg protein/mi assay volume) on cyclo-oxygenase (Figure 3A) or lipo-oxygenase
metabolites (Figure 3B) in human platelets.

Discussion
The results of the present study demonstrate that HDL and LDL exert inhibitory effects on AA
metabolism in human platelets. HDL decreased the fOrmation of TXA2 and 12-HETE in platelets
suggesting that it has an inhibitory effect on both cyclo- oxygenase and lipoxygenase pathways of AA
metabolism. The magnitude of inhibition was dependent upon the protein concentration of HDL. Like
HDL, LDL decreased the fonnation of TXA2 in a concentration dependent-manner indicating that LDL
also has inhibitory effect on cyclo-oxygenase pathways of AA metabolism. On the other hand, LDL had
a weak inhibitory effect on 12-HETE formation in human platelets which was only observed at high
protein concentrations.
In contrast to HDL and LDL, VLDL had no significant effect on either TXA2 or 12-HETE formation in
human platelets. The reason for this lack of VLDL effect on AA metabolism in platelets is not clear,
however, it could be related to the composition of different lipoproteins. VLDL consists of mainly
triglycerides as compared to LDL and HDL which contain cholesterol as their primary lipid

component5,6. Moreover, the major apoproteins associated with HDL, LDL and also different and have
different functional roles5,6. The differences in the apoproteins associated with LDL and HDL may be
responsible for the differences in the rñagmtude of their effects on lipooxygenase metabolites. Thus, it
is likely that the differential effects of lipoproteins on AA metabolism may be related to the unique
composition of individual lipoproteins. Both TXA2 and 12-HETE play an important role in platelet
shape change, adhesion and aggregation1,18 and these changes play a significant role in the progression
of atherosclerosis19. Wile TXA2 is a major pro- aggregatory agent, the role of 12-HETE has been
confined to platelet shape change and chemotaxis 20. High HDL levels are considered a protective
factor against coronary heart disease because of their role in ‘reverse cholesterol transport’ and are
associated witha decreased risk of atherosclerosis21. It has been shown by Coil et al22 that HDL can
inhibit platelet aggregation induced by a variety of aggregating agents. The inhibitory effects of HDL
on TXA2 and 12-HETE formation shown in this study suggestanew beneficial and protective role
forHDL whereby, it may decrease the formation of pro-aggregatoiy and chemotactic cicosanoids which
are involved in the progression of atherogenesis20. The significance of the inhibitory effects of LDL on
TXA2 formation in humans platelets is not clear as raised plasma levels of LDL are considered a
positive risk factor for coronary heart disease7. However, these studies were conducted on lipoproteins
isolated from normal healthy volunteers whose plasma lipoprotein levels were in the normal range. It is
likely that LDL isolated from patients with coronary heart disease may behave differently as these
patients have a substantial increase in oxidized LDL which is mainly responsible for increasing the
atherogenic potential of LDL23.
In addition to theirrole in lipid transport and modulatory effects on AA metabolism, lipoproteins have
been shown to exert other effects. Several studies have now reported that chylomicrons, VLDL, LDL
and HDL can bind to endotoxin and prevent its ability to induce fever, hypotension or death in
rodents24-26. On quantitative basis, HDL appears to be the most important contributor to host defence
against bacterial endotoxin27. Lipoproteins can also decrease endotoxin-induced cytokine secretion by
macrophagcs27,28 and thereby decrease their toxic effects30. The ability of HDL and LDL to inhibit the
production of TXA2 and 12-FIETE which are the mediators ofinflaniniatory responses may be an
additional non-specific mechanism which may be operative in host defence in several disease states and
inflammatory conditions where lipopmteins are usually elevated. In summary our results indicate that
HDL and LDL have significant inhibitory effects on TXA2 and 12-HETE fonnation suggesting that
lipoproteins may have a physiological role in the regulation of AA metabolism in platelets. Since
lipopmteins levels are elevated in several conditions such as coronary heart disease, chronic renal
failure, diabetes mellitus and chronic infections7,30-32 it is likely that they may modulate a wide range
of biological effects of different AA metabolites in the pathophysiology of these diseases.
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